Employer groups praised a bill aimed at boosting healthcare competition and lowering costs by banning anticompetitive insurer-provider contracts. The post Employer Groups Applaud Bill that Aims to Spur Competition in Healthcare appeared first on MedCity News.
A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing development of the oral drug in diabetic peripheral neuropathy. The post Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study appeared first on…
Shareholders could also get another $2.7 billion from future sale(s) of VillageMD assets.
By OWEN TRIPP Creating a healthcare experience that builds trust and delivers value to people and purchasers isn’t a quick fix, but it’s the only way to reverse the downward spiral of high costs and poor outcomes Entrepreneurs like to say the U.S. healthcare system is “broken,” usually right before they explain how they intend…
ISPOR Europe kicks off this week in Barcelona, Spain. In honor of ISPOR, I will summarize some key attributes of the Spanish health care system based on a 2024 report from the European Observatory on Health Systems and Policies and the Instituto Aragones de Ciencias de la Salud. Country overview Population: 48.4 million (as of…
Hundreds of people in and around Los Angeles are still picking up the pieces after devastating fires swept through the county in January. The wildfires erupted on January 7th, 2025, destroying communities in the Palisades and Eaton neighborhoods and elsewhere. Many people lost their homes, and dozens lost their lives. As these communities struggled with…
[Sponsored] In this latest episode, Arundhati explores how one Mayo Clinic doctor found purpose in her deeply personal tragedy and how Mayo Clinic Florida then took her idea, executed on it and is attempting to scale it. The post MedCity Pivot Podcast: Mayo Clinic Florida Redefines Cancer Care appeared first on MedCity News.
It seems like the answer is now ‘yes’. EndPoints reports: Stealth BioTherapeutics said the FDA would not meet its Tuesday deadline for approving or rejecting the company’s drug, elamipretide. It had been seeking regulatory clearance of elamipretide for a rare disease called Barth syndrome, which affects only about 150 people in the US and causes…
By KIM BELLARD These are, it must be said, grim times for American science. Between the Trump budget cuts, the Trump attacks on leading research universities, and the normalization of misinformation/ disinformation, scientists are losing their jobs, fleeing to other countries, or just trying to keep their heads down in hopes of being able to…
Families USA hosts a press conference discussing how rising healthcare premiums and expiring healthcare tax credits will impact working families nationwide